These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9078447)
21. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Marco F; Pfaller MA; Messer SA; Jones RN Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755 [TBL] [Abstract][Full Text] [Related]
22. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Pfaller MA; Messer SA; Rhomberg PR; Castanheira M Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853 [TBL] [Abstract][Full Text] [Related]
23. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Jacobsen MD; Whyte JA; Odds FC Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974 [TBL] [Abstract][Full Text] [Related]
24. The echinocandins. Cappelletty D; Eiselstein-McKitrick K Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149 [TBL] [Abstract][Full Text] [Related]
25. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). Messer SA; Kirby JT; Sader HS; Fritsche TR; Jones RN J Antimicrob Chemother; 2004 Dec; 54(6):1051-6. PubMed ID: 15564286 [TBL] [Abstract][Full Text] [Related]
26. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556 [TBL] [Abstract][Full Text] [Related]
27. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Karlowsky JA; Hoban DJ; Zhanel GG; Goldstein BP Int J Antimicrob Agents; 2006 Feb; 27(2):174-7. PubMed ID: 16414247 [TBL] [Abstract][Full Text] [Related]
28. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Locke JB; Almaguer AL; Donatelli JL; Bartizal KF Infect Dis Obstet Gynecol; 2018; 2018():7040498. PubMed ID: 29681727 [TBL] [Abstract][Full Text] [Related]
29. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Chamilos G; Lewis RE; Albert N; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Jun; 51(6):2257-9. PubMed ID: 17438060 [TBL] [Abstract][Full Text] [Related]
30. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448 [TBL] [Abstract][Full Text] [Related]
31. Susceptibility of Candida species to cilofungin (LY-121019). Torres-Rodriguez JM; Carrillo-Muñoz A; Gallach-Bau C; Madrenys N Mycoses; 1989 Jun; 32(6):316-8. PubMed ID: 2779613 [TBL] [Abstract][Full Text] [Related]
32. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Espinel-Ingroff A Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves. Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G Diagn Microbiol Infect Dis; 2015 May; 82(1):57-61. PubMed ID: 25703894 [TBL] [Abstract][Full Text] [Related]
35. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561 [TBL] [Abstract][Full Text] [Related]
36. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Choi HW; Shin JH; Jung SI; Park KH; Cho D; Kee SJ; Shin MG; Suh SP; Ryang DW Antimicrob Agents Chemother; 2007 Apr; 51(4):1520-3. PubMed ID: 17283191 [TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851 [TBL] [Abstract][Full Text] [Related]
38. [Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus]. Ohta C; Yamane N; Nakasone I; Onaga S; Nakamura K Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2005; 16(2):127-33. PubMed ID: 16536058 [TBL] [Abstract][Full Text] [Related]
39. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079 [TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B. Meunier F; Lambert C; Van der Auwera P J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]